As at 31 March 2024, 34 out of a total target of 45 patients have been randomised
and have initiated treatment.
An additional 7 patients are currently in screening or anticipated to shortly
commence screening, and it is expected that the majority will be randomised in
coming weeks.
To date, 9 patients have successfully transitioned into the open-label extension
phase of the study, in which all patients receive ATL1102. No patients have
withdrawn from the study. The adverse events seen in the study thus far are
generally minor in severity and consistent with prior clinical experience.
Seems like we are about done with the recruitment, hopefully in the next 2 weeks. Stay tuned!
As at 31 March 2024, 34 out of a total target of 45 patients...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |